A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Crohn's Disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504737-41-00

Acronym

CNTO1959CRD3004

Enrollment

219

Registered

2024-07-18

Start date

2022-06-10

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderately to Severely Active Crohn's Disease

Brief summary

Clinical remission at Week 12, Endoscopic response at Week 12

Interventions

DRUGPlacebo for Guselkumab

DRUGGuselkumab - solution for injection in pre-filled syringe - 100 mg/mL

DRUGGuselkumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Clinical remission at Week 12, Endoscopic response at Week 12	—

Countries

Croatia, Czechia, France, Germany, Hungary, Italy, Lithuania, Poland, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026